Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm

被引:8
|
作者
Nishino, Mizuki [1 ,2 ]
Wakai, Satoshi [3 ]
Hida, Tomoyuki [1 ,2 ]
Dahlberg, Suzanne E. [4 ]
Ozaki, Masahiro [3 ]
Hatabu, Hiroto [1 ,2 ]
Tachizaki, Hisashi [3 ]
Johnson, Bruce E. [5 ,6 ,7 ]
机构
[1] Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[3] Canon Med Syst Corp, 1385 Shimoishigami, Otawara, Tochigi 3248550, Japan
[4] Dana Farber Canc Inst, Dept Biostat, 450 Brookline Ave, Boston, MA 02215 USA
[5] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Dept Med, 450 Brookline Ave, Boston, MA 02215 USA
[7] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
Lung cancer; Epidermal growth factor receptor; EGFR inhibitor; Computed tomography; Tumor growth rate; DIFFERENT TREATMENT MODALITIES; RESPONSE EVALUATION CRITERIA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; NSCLC PATIENTS; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; PROGRESSION;
D O I
10.1016/j.ejrad.2018.10.014
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To develop an automated analytic module for calculation of tumor growth rate from serial CT scans and to apply the module and evaluate reproducibility in a pilot cohort of advanced NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors. Materials and methods: The module utilized a commercially available image-processing workstation equipped with a validated tumor volume measurement tool. An automated analytic software module was programmed with the capability to record and display serial tumor volume changes and to calculate tumor volume growth rate over time and added to the workstation. The module was applied to evaluate the tumor growth rate in a pilot cohort of 24 EGFR-mutant patients treated with EGFR inhibitors, and reproducibility references as tested by two independent thoracic radiologists. Results: The module analyzed chest CT scans from 24 patients (5 males, 19 females; median age: 61) with a median of 8 scans per patient, totaling 227 scans and provided a graphical display with an automated and instant calculation of tumor growth rate after the nadir volume for each patient. High inter and intraobserver agreements were noted for tumor growth rates, with concordance correlation coefficients of 0.9323 and 0.9668, respectively. Interpretation of slow versus fast tumor growth using previously identified threshold of <= 0.15/month had a perfect interobserver agreement (kappa = 1.00), and an excellent intraobserver agreement (kappa = 0.895). Conclusions: The present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 50 条
  • [41] Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
    Paz-Ares, Luis
    Soulieres, Denis
    Melezinek, Ivan
    Moecks, Joachim
    Keil, Lorenz
    Mok, Tony
    Rosell, Rafael
    Klughammer, Barbara
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (1-2) : 51 - 69
  • [42] Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET
    Arvold, Nils D.
    Heidari, Pedram
    Kunawudhi, Anchisa
    Sequist, Lecia V.
    Mahmood, Umar
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2016, 15 (02) : 234 - 242
  • [43] Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
    Loong, Herbert H.
    Kwan, Sui-chun Sampson
    Mok, Tony Shu-kam
    Lau, Yat-ming
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
  • [44] Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Jin, Rui
    Zhao, Jing
    Xia, Lexin
    Li, Qin
    Li, Wen
    Peng, Ling
    Xia, Yang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [45] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [46] Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancer
    Lin, Chien-Yu
    Chou, Yun-Tse
    Su, Po-Lan
    Lin, Chien-Chung
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Yang, Cheng-Ta
    Wu, Chiao-En
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (09): : 4208 - +
  • [47] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Zhu, Viola W.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
  • [48] What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer
    Liu, Si-Yang
    Zhang, Jia-Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 217 - +
  • [49] Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer
    Giovannetti, Elisa
    Erdem, Lale
    Olcay, Efnan
    Leon, Leticia G.
    Peters, Godefridus J.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 116 - 130
  • [50] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040